<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33003004</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-6899</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Continuum (Minneapolis, Minn.)</Title><ISOAbbreviation>Continuum (Minneap Minn)</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases.</ArticleTitle><Pagination><StartPage>1323</StartPage><EndPage>1347</EndPage><MedlinePgn>1323-1347</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/CON.0000000000000911</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW">This article reviews the clinical features, diagnostic approach, and treatments available for amyotrophic lateral sclerosis (ALS) and other motor neuron diseases. The article also provides an update on the genetics and pathophysiology of ALS.</AbstractText><AbstractText Label="RECENT FINDINGS">ALS remains a clinical diagnosis without a unique biomarker. The areas of greatest progress include a large expansion in the number of genes associated with familial and sporadic ALS. The discovery of these genes, along with other work, has provided a deeper understanding of the mechanisms of motor neuron failure in ALS. Areas of particular interest include the role of transactive response DNA-binding protein 43 and other RNA-processing proteins in the development of disease.</AbstractText><AbstractText Label="SUMMARY">ALS remains a relentlessly progressive disorder with an elusive core pathophysiology. The current mainstay of treatment remains symptom management and palliation, particularly in the setting of a multidisciplinary clinic. The future holds potential for targeted therapies based on an ever-evolving understanding of the pathophysiology of both familial and sporadic ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Elman</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Continuum (Minneap Minn)</MedlineTA><NlmUniqueID>9509333</NlmUniqueID><ISSNLinking>1080-2371</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>1</Day><Hour>20</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33003004</ArticleId><ArticleId IdType="doi">10.1212/CON.0000000000000911</ArticleId><ArticleId IdType="pii">00132979-202010000-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 2013;9(11):617&#x2013;628. doi:10.1038/nrneurol.2013.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 2013;41(2):118&#x2013;130. doi:10.1159/000351153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston CA, Stanton BR, Turner MR, et al. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol 2006;253(12):1642&#x2013;1643. doi:10.1007/s00415-006-0195-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-006-0195-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Manjaly ZR, Scott KM, Abhinav K, et al. The sex ratio in amyotrophic lateral sclerosis: a population based study. Amyotroph Lateral Scler 2010;11(5):439&#x2013;442. doi:10.3109/17482961003610853.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482961003610853</ArticleId></ArticleIdList></Reference><Reference><Citation>Traxinger K, Kelly C, Johnson BA, et al. Prognosis and epidemiology of amyotrophic lateral sclerosis: analysis of a clinic population, 1997&#x2013;2011. Neurol Clin Pract 2013;3(4):313&#x2013;320. doi:10.1212/CPJ.0b013e3182a1b8ab.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CPJ.0b013e3182a1b8ab</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Fang F, Hanby MF, et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry 2010;81(12):1324&#x2013;1326. doi:10.1136/jnnp.2010.207464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.207464</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Shih T, Stern Y, et al. Premorbid weight, body mass, and varsity athletics in ALS. Neurology 2002;59(5):773&#x2013;775. doi:10.1212/wnl.59.5.773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.59.5.773</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman MH, Seelen M, de Jong SW, et al. Lifetime physical activity and the risk of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2013;84(9):976&#x2013;981. doi:10.1136/jnnp-2012-304724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-304724</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutedja NA, van der Schouw YT, Fischer K, et al. Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011;82(6):638&#x2013;642. doi:10.1136/jnnp.2010.236752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.236752</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Reilly &#xc9;J, Wang H, Weisskopf MG, et al. Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2013;14(3):205&#x2013;211. doi:10.3109/21678421.2012.735240.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.735240</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Benzi G, Dossena M, et al. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain 2005;128(pt 3):472&#x2013;476. doi:10.1093/brain/awh373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh373</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehman EJ, Hein MJ, Baron SL, Gersic CM. Neurodegenerative causes of death among retired National Football League players. Neurology 2012;79(19):1970&#x2013;1974. doi:10.1212/WNL.0b013e31826daf50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31826daf50</ArticleId></ArticleIdList></Reference><Reference><Citation>Blecher R, Elliott MA, Yilmaz E, et al. Contact sports as a risk factor for amyotrophic lateral sclerosis: a systematic review. Global Spine J 2019;9(1):104&#x2013;118. doi:10.1177/2192568218813916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2192568218813916</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisskopf MG, O'Reilly EJ, McCullough ML, et al. Prospective study of military service and mortality from ALS. Neurology 2005;64(1):32&#x2013;37. doi:10.1212/01.WNL.0000148649.17706.D9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000148649.17706.D9</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisskopf MG, Cudkowicz ME, Johnson N. Military service and amyotrophic lateral sclerosis in a population-based cohort. Epidemiology 2015;26(6):831&#x2013;838. doi:10.1097/EDE.0000000000000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000000376</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutedja NA, Fischer K, Veldink JH, et al. What we truly know about occupation as a risk factor for ALS: a critical and systematic review. Amyotroph Lateral Scler 2009;10(5&#x2013;6):295&#x2013;301. doi:10.3109/17482960802430799.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802430799</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutedja NA, Veldink JH, Fischer K, et al. Exposure to chemicals and metals and risk of amyotrophic lateral sclerosis: a systematic review. Amyotroph Lateral Scler 2009;10(5&#x2013;6):302&#x2013;309. doi:10.3109/17482960802455416.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802455416</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson LM, McGuire V, Longstreth WT Jr, Matkin C. Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption. Am J Epidemiol 2000;151(2):156&#x2013;163. doi:10.1093/oxfordjournals.aje.a010183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a010183</ArticleId></ArticleIdList></Reference><Reference><Citation>Armon C. Smoking may be considered an established risk factor for sporadic ALS. Neurology 2009;73(20):1693&#x2013;1698. doi:10.1212/WNL.0b013e3181c1df48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c1df48</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A, Logroscino G, Jick SS, Hern&#xe1;n MA. Association of smoking with amyotrophic lateral sclerosis risk and survival in men and women: a prospective study. BMC Neurol 2010;10:6. doi:10.1186/1471-2377-10-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-10-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisskopf MG, McCullough ML, Calle EE, et al. Prospective study of cigarette smoking and amyotrophic lateral sclerosis. Am J Epidemiol 2004;160(1):26&#x2013;33. doi:10.1093/aje/kwh179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwh179</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, O'Reilly &#xc9;J, Weisskopf MG, et al. Smoking and risk of amyotrophic lateral sclerosis: a pooled analysis of 5 prospective cohorts. Arch Neurol 2011;68(2):207&#x2013;213. doi:10.1001/archneurol.2010.367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.367</ArticleId></ArticleIdList></Reference><Reference><Citation>Bienfang PK, Defelice SV, Laws EA, et al. Prominent human health impacts from several marine microbes: history, ecology, and public health implications. Int J Microbiol 2011;2011:152815. doi:10.1155/2011/152815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/152815</ArticleId></ArticleIdList></Reference><Reference><Citation>Abhinav K, Al-Chalabi A, Hortobagyi T, Leigh PN. Electrical injury and amyotrophic lateral sclerosis: a systematic review of the literature. J Neurol Neurosurg Psychiatry 2007;78(5):450&#x2013;453. doi:10.1136/jnnp.2006.104414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2006.104414</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol 2016;138:225&#x2013;238. doi:10.1016/B978-0-12-802973-2.00013-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-802973-2.00013-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedermeyer S, Murn M, Choi PJ. Respiratory failure in amyotrophic lateral sclerosis. Chest 2019;155(2):401&#x2013;408. doi:10.1016/j.chest.2018.06.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2018.06.035</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarmento A, Fregonezi G, Dourado-Junior MET, et al. Thoracoabdominal asynchrony and paradoxical motion in middle stage amyotrophic lateral sclerosis. Respir Physiol Neurobiol 2019;259:16&#x2013;25. doi:10.1016/j.resp.2018.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resp.2018.06.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapchak PA. Neuronal dysregulation in stroke-associated pseudobulbar affect (PBA): diagnostic scales and current treatment options. J Neurol Neurophysiol 2015;6(5):323. doi:10.4172/2155-9562.1000323.</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2155-9562.1000323</ArticleId></ArticleIdList></Reference><Reference><Citation>Floeter MK, Katipally R, Kim MP, et al. Impaired corticopontocerebellar tracts underlie pseudobulbar affect in motor neuron disorders. Neurology 2014;83(7):620&#x2013;627. doi:10.1212/WNL.0000000000000693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000693</ArticleId></ArticleIdList></Reference><Reference><Citation>Marie P. Le&#xe7;ons sur les maladies de la moelle. Paris, France: G. Masson, 1892.</Citation></Reference><Reference><Citation>Massman PJ, Sims J, Cooke N, et al. Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1996;61(5):450&#x2013;455. doi:10.1136/jnnp.61.5.450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.61.5.450</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomen-Hoerth C, Murphy J, Langmore S, et al. Are amyotrophic lateral sclerosis patients cognitively normal?Neurology 2003;60(7):1094&#x2013;1097. doi:10.1212/01.wnl.0000055861.95202.8d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000055861.95202.8d</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy J, Factor-Litvak P, Goetz R, et al. Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort. Neurology 2016;86(9):813&#x2013;820. doi:10.1212/WNL.0000000000002305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002305</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 2017;18(3&#x2013;4):153&#x2013;174. doi:10.1080/21678421.2016.1267768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinceti G, Olney N, Mandelli ML, et al. Primary progressive aphasia and the FTD-MND spectrum disorders: clinical, pathological, and neuroimaging correlates. Amyotroph Lateral Scler Frontotemporal Degener 2019;20(3&#x2013;4):146&#x2013;158. doi:10.1080/21678421.2018.1556695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1556695</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002;59(7):1077&#x2013;1079. doi:10.1212/wnl.59.7.1077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.59.7.1077</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell JR, Kiernan MC, Vucic S, Hodges JR. Motor neuron dysfunction in frontotemporal dementia. Brain 2011;134(pt 9):2582&#x2013;2594. doi:10.1093/brain/awr195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr195</ArticleId></ArticleIdList></Reference><Reference><Citation>Niven E, Newton J, Foley J, et al. Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): a cognitive tool for motor disorders. Amyotroph Lateral Scler Frontotemporal Degener 2015;16(3&#x2013;4):172&#x2013;179. doi:10.3109/21678421.2015.1030430.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1030430</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolley SC, York MK, Moore DH, et al. Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS). Amyotroph Lateral Scler 2010;11(3):303&#x2013;311. doi:10.3109/17482961003727954.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482961003727954</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A, Drory V, Hardiman O, et al. A revision of the El Escorial criteria &#x2013; 2015. Amyotroph Lateral Scler Frontotemporal Degener 2015;16(5&#x2013;6):291&#x2013;292. doi:10.3109/21678421.2015.1049183.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1049183</ArticleId></ArticleIdList></Reference><Reference><Citation>Nodera H, Izumi Y, Kaji R. New diagnostic criteria of ALS (Awaji criteria) [in Japanese]. Brain Nerve 2007;59(10):1023&#x2013;1029.</Citation></Reference><Reference><Citation>Roche JC, Rojas-Garcia R, Scott KM, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain 2012;135(pt 3):847&#x2013;852. doi:10.1093/brain/awr351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr351</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Hammond ER, Mora G, et al. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2015;86(1):38&#x2013;44. doi:10.1136/jnnp-2013-306589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-306589</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Stahl DR, et al. Comparison of the King's and MiToS staging systems for ALS. Amyotroph Lateral Scler Frontotemporal Degener 2017;18(3&#x2013;4):227&#x2013;232. doi:10.1080/21678421.2016.1265565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1265565</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwathmey K. Chronic inflammatory demyelinating polyradiculoneuropathy and its variants. Continuum (Minneap Minn) 2020;26(5, Peripheral Nerve and Motor Neuron Disorders):1204&#x2013;1222.</Citation></Reference><Reference><Citation>Nobile-Orazio E, Giannotta C, Musset L, et al. Sensitivity and predictive value of anti-GM1/galactocerebroside IgM antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2014;85(7):754&#x2013;758. doi:10.1136/jnnp-2013-305755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-305755</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowen LN, Tyagi R, Li W, et al. HIV-associated motor neuron disease: HERV-K activation and response to antiretroviral therapy. Neurology 2016;87(17):1756&#x2013;1762. doi:10.1212/WNL.0000000000003258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003258</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, De Schaepdryver M, Dedeene L, et al. Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis?J Neurol Neurosurg Psychiatry 2019;90(12):1338&#x2013;1346. doi:10.1136/jnnp-2018-319586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319586</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Boylan K, Jeromin A, et al. ALS biomarkers for therapy development: state of the field and future directions. Muscle Nerve 2016;53(2):169&#x2013;182. doi:10.1002/mus.24979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24979</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayakumar UG, Milla V, Cynthia Stafford MY, et al. A systematic review of suggested molecular strata, biomarkers and their tissue sources in ALS. Front Neurol 2019;10:400. doi:10.3389/fneur.2019.00400.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00400</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori F, Kakita A, Takahashi H, Wakabayashi K. Co-localization of Bunina bodies and TDP-43 inclusions in lower motor neurons in amyotrophic lateral sclerosis. Neuropathology 2014;34(1):71&#x2013;76. doi:10.1111/neup.12044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12044</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314(5796):130&#x2013;133. doi:10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId></ArticleIdList></Reference><Reference><Citation>Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci 2013;14(4):248&#x2013;264. doi:10.1038/nrn3430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3430</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009;323(5918):1205&#x2013;1208. doi:10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Rogelj B, Hortob&#xe1;gyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009;323(5918):1208&#x2013;1211. doi:10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId></ArticleIdList></Reference><Reference><Citation>Laaksovirta H, Peuralinna T, Schymick JC, et al. Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurol 2010;9(10):978&#x2013;985. doi:10.1016/S1474-4422(10)70184-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70184-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72(2):257&#x2013;268. doi:10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72(2):245&#x2013;256. doi:10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012;11(4):323&#x2013;330. doi:10.1016/S1474-4422(12)70043-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70043-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Konno T, Shiga A, Tsujino A, et al. Japanese amyotrophic lateral sclerosis patients with GGGGCC hexanucleotide repeat expansion in C9ORF72. J Neurol Neurosurg Psychiatry 2013;84(4):398&#x2013;401. doi:10.1136/jnnp-2012-302272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-302272</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy NA, Arthur KC, Tienari PJ, et al. Age-related penetrance of the C9orf72 repeat expansion. Sci Rep 2017;7(1):2116. doi:10.1038/s41598-017-02364-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-02364-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg MA, Sundaramoorthy V, Sultana JM, et al. C9ORF72, implicated in amyotrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum Mol Genet 2014;23(13):3579&#x2013;3595. doi:10.1093/hmg/ddu068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu068</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatsavayai SC, Nana AL, Yokoyama JS, Seeley WW. C9orf72-FTD/ALS pathogenesis: evidence from human neuropathological studies. Acta Neuropathol 2019;137(1):1&#x2013;26. doi:10.1007/s00401-018-1921-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1921-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, L&#xf3;pez-Erauskin J, Baughn MW, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci 2019;22(2):180&#x2013;190. doi:10.1038/s41593-018-0293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 2002;26(4):459&#x2013;470. doi:10.1002/mus.10191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.10191</ArticleId></ArticleIdList></Reference><Reference><Citation>Geloso MC, Corvino V, Marchese E, et al. The dual role of microglia in ALS: mechanisms and therapeutic approaches. Front Aging Neurosci 2017;9:242. doi:10.3389/fnagi.2017.00242.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00242</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooten KG, Beers DR, Zhao W, Appel SH. Protective and toxic neuroinflammation in amyotrophic lateral sclerosis. Neurotherapeutics 2015;12(2):364&#x2013;375. doi:10.1007/s13311-014-0329-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0329-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M, Evangelopoulos E, Sereti E, et al. Alterations of T cell subsets in ALS: a systemic immune activation?Acta Neurol Scand 2012;125(4):260&#x2013;264. doi:10.1111/j.1600-0404.2011.01528.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2011.01528.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Werdelin L, Boysen G, Jensen TS, Mogensen P. Immunosuppressive treatment of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 1990;82(2):132&#x2013;134. doi:10.1111/j.1600-0404.1990.tb01602.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1990.tb01602.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Meucci N, Nobile-Orazio E, Scarlato G. Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. J Neurol 1996;243(2):117&#x2013;120. doi:10.1007/bf02444000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/bf02444000</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier CN, Schoenfeld D, Berry JD, et al. An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2018;19(3&#x2013;4):242&#x2013;249. doi:10.1080/21678421.2017.1421666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1421666</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Genge A, Chio A, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener 2020;21(1&#x2013;2);5&#x2013;14. doi:10.1080/21678421.2019.1632346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Mizwicki MT, Weitzman R, et al. Tocilizumab infusion therapy normalizes inflammation in sporadic ALS patients. Am J Neurodegener Dis 2013;2(2):129&#x2013;139.</Citation></Reference><Reference><Citation>Mandrioli J, D'Amico R, Zucchi E, et al. Rapamycin treatment for amyotrophic lateral sclerosis: protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial). Medicine (Baltimore) 2018;97(24):e11119. doi:10.1097/MD.0000000000011119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000011119</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.gov. T-regulatory Cells in ALS (Tregs in ALS). clinicaltrials.gov/ct2/show/NCT04055623. Accessed August 5, 2020.</Citation></Reference><Reference><Citation>Kern R, Cudkowicz M, Berry J, et al. NurOwn&#xae; Phase 2 ALS study: ALSFRS-R subscale responder analysis. Paper presented at: 70th Annual Meeting of the American Academy of Neurology; April 21&#x2013;27, 2018; Los Angeles, CA. S38.002.</Citation></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330(9):585&#x2013;591. doi:10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012;(2):CD001447. doi:10.1002/14651858.CD001447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001447</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017;16(7):505&#x2013;512. doi:10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Maragakis NJ. What can we learn from the edaravone development program for ALS?Amyotroph Lateral Scler Frontotemporal Degener 2017;18(suppl 1):98&#x2013;103. doi:10.1080/21678421.2017.1361446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1361446</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei K, Tsuda K, Takahashi F, Palumbo J. Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2017;18(suppl 1):64&#x2013;70. doi:10.1080/21678421.2017.1365372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1365372</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin S, Trevor-Jones E, Khan S, et al. The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparison. Amyotroph Lateral Scler Frontotemporal Degener 2017;18(7&#x2013;8):569&#x2013;575. doi:10.1080/21678421.2017.1349151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1349151</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Alexander M, Corr B, et al. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996&#x2013;2000. J Neurol Neurosurg Psychiatry 2003;74(9):1258&#x2013;1261. doi:10.1136/jnnp.74.9.1258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.74.9.1258</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs TL, Brown DL, Baek J, et al. Trial of early noninvasive ventilation for ALS: a pilot placebo-controlled study. Neurology 2016;87(18):1878&#x2013;1883. doi:10.1212/WNL.0000000000003158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003158</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleopa KA, Sherman M, Neal B, et al. BiPAP improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci 1999;164(1):82&#x2013;88. doi:10.1016/s0022-510x(99)00045-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(99)00045-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourke SC, Tomlinson M, Williams TL, et al. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006;5(2):140&#x2013;147. doi:10.1016/S1474-4422(05)70326-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(05)70326-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73(15):1218&#x2013;1226. doi:10.1212/WNL.0b013e3181bc0141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181bc0141</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73(15):1227&#x2013;1233. doi:10.1212/WNL.0b013e3181bc01a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181bc01a4</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell JR, Vucic S, Kiernan MC. Isolated bulbar phenotype of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2011;12(4):283&#x2013;289. doi:10.3109/17482968.2011.551940.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.551940</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawdat O, Statland JM, Barohn RJ, et al. Amyotrophic lateral sclerosis regional variants (brachial amyotrophic diplegia, leg amyotrophic diplegia, and isolated bulbar amyotrophic lateral sclerosis). Neurol Clin 2015;33(4):775&#x2013;785. doi:10.1016/j.ncl.2015.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WK, Liu X, Sandner J, et al. Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology 2009;73(20):1686&#x2013;1692. doi:10.1212/WNL.0b013e3181c1dea3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c1dea3</ArticleId></ArticleIdList></Reference><Reference><Citation>Ince PG, Evans J, Knopp M, et al. Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS. Neurology 2003;60(8):1252&#x2013;1258. doi:10.1212/01.wnl.0000058901.75728.4e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000058901.75728.4e</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Stein B, Partain M, et al. Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy. Acta Neuropathol 2011;121(4):509&#x2013;517. doi:10.1007/s00401-011-0797-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0797-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Riku Y, Atsuta N, Yoshida M, et al. Differential motor neuron involvement in progressive muscular atrophy: a comparative study with amyotrophic lateral sclerosis. BMJ Open 2014;4(5):e005213. doi:10.1136/bmjopen-2014-005213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2014-005213</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Barohn RJ, Corcia P, et al. Primary lateral sclerosis: consensus diagnostic criteria. J Neurol Neurosurg Psychiatry 2020;91(4):373&#x2013;377. doi:10.1136/jnnp-2019-322541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-322541</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehman VT, Luetmer PH, Sorenson EJ, et al. Cervical spine MR imaging findings of patients with Hirayama disease in North America: a multisite study. AJNR Am J Neuroradiol 2013;34(2):451&#x2013;456. doi:10.3174/ajnr.A3277.</Citation><ArticleIdList><ArticleId IdType="doi">10.3174/ajnr.A3277</ArticleId></ArticleIdList></Reference><Reference><Citation>Boruah DK, Prakash A, Gogoi BB, et al. The importance of flexion MRI in Hirayama disease with special reference to laminodural space measurements. AJNR Am J Neuroradiol 2018;39(5):974&#x2013;980. doi:10.3174/ajnr.A5577.</Citation><ArticleIdList><ArticleId IdType="doi">10.3174/ajnr.A5577</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirayama K, Tokumaru Y. Cervical dural sac and spinal cord in juvenile muscular atrophy of distal upper extremity. Neurology 2000;54(10):1922&#x2013;1926. doi:10.1212/wnl.54.10.1922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.54.10.1922</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirayama K. Juvenile muscular atrophy of distal upper extremity (Hirayama disease): focal cervical ischemic poliomyelopathy. Neuropathology 2000;20(suppl):S91&#x2013;S94. doi:10.1046/j.1440-1789.2000.00305.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1440-1789.2000.00305.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn C, Paganoni S, Cochrane T. Clinical improvement of monomelic amyotrophy after avoidance of sustained neck flexion. J Clin Neuromuscul Dis 2014;15(4):191&#x2013;192. doi:10.1097/CND.0000000000000028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CND.0000000000000028</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiba S, Yonekura K, Nonaka M, et al. Advanced Hirayama disease with successful improvement of activities of daily living by operative reconstruction. Intern Med 2004;43:79&#x2013;81. doi:10.2169/internalmedicine.43.79.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.43.79</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H, Takai K, Taniguchi M. Cervical duraplasty with tenting sutures via laminoplasty for cervical flexion myelopathy in patients with Hirayama disease: successful decompression of a &#x201c;tight dural canal in flexion&#x201d; without spinal fusion. J Neurosurg Spine 2014;21:743&#x2013;752. doi:10.3171/2014.7.SPINE13955.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/2014.7.SPINE13955</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Adachi H, Doyu M, et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 2003;9(6):768&#x2013;773. doi:10.1038/nm878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm878</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Adachi H, Kume A, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 2002;35(5):843&#x2013;854. doi:10.1016/s0896-6273(02)00834-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0896-6273(02)00834-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes LE, Freeman BK, Auh S, et al. Clinical features of spinal and bulbar muscular atrophy. Brain 2009;132(pt 12):3242&#x2013;3251. doi:10.1093/brain/awp258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp258</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada AR, Roling DB, Harding AE, et al. Meiotic stability and genotype-phenotype correlation of the trinucleotide repeat in X-linked spinal and bulbar muscular atrophy. Nat Genet 1992;2(4):301&#x2013;304. doi:10.1038/ng1292-301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1292-301</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K, Katsuno M, Banno H, et al. CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA. Brain 2008;131(pt 1):229&#x2013;239. doi:10.1093/brain/awm289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm289</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Rhodes LE, Kokkinis AD, White MJ, et al. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol 2011;10(2):140&#x2013;147. doi:10.1016/S1474-4422(10)70321-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70321-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Suzuki K, et al. Efficacy and safety of leuprorelin acetate for subjects with spinal and bulbar muscular atrophy: pooled analyses of two randomized-controlled trials. J Neurol 2019;266(5):1211&#x2013;1221. doi:10.1007/s00415-019-09251-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09251-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunseich C, Miller R, Swan T, et al. Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial. Lancet Neurol 2018;17(12):1043&#x2013;1052. doi:10.1016/S1474-4422(18)30320-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30320-X</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>